A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

Yamamoto N.Ryoo B.-Y.Keam B.Kudo M.CHIA-CHI LINKunieda F.Ball H.A.Moran D.Komatsu K.Takeda K.Fukuda M.Furuse J.Morita S.Doi T.2022-09-152022-09-1520200167-6997https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065226846&doi=10.1007%2fs10637-019-00780-w&partnerID=40&md5=c1e1a10591d124cea39cd684628602c9https://scholars.lib.ntu.edu.tw/handle/123456789/620238A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignanciesjournal article10.1007/s10637-019-00780-w310415752-s2.0-85065226846